Trading--Inverse Equity · NASDAQ · USD · Data as of 2026-07-30
AUM
$2.25M
Expense ratio
0.95%
Yield
5.79%
YTD return
-27.03%
Last price
$13.78
Leveraged · Coverage 63% · medium
Today
41.1
Outlook
42.7
Block A (composite-derived)
37.7
Block C (market behavior)
38.3
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
37.7
Coverage 63% · medium
Liquidity
5.0
Expenses
45.0
Performance
33.1
Volatility
63.1
Dividend
44.4
Concentration
—
Smart Money
—
Activist
—
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
ProShares UltraShort Nasdaq Biotechnology (BIS) is an exchange-traded fund from ProShares in the Mixed asset class. Launched in 2010. Assets under management: 2,453,929.
Bullish Whales composite rating: 38 out of 100. Evidence coverage 63% across 5 of 8 axes. Strongest axes: volatility, expenses, dividend.
Annualized one-year realized volatility 80%, classified high. Weakest axes: liquidity, performance.
Trailing yield 0%.
etf_composite_score_current · composite_score, confidence, coverage_pct, dividend_score, expenses_score, liquidity_score, performance_score, volatility_scoreetf_fundamentals_td · dividend_frequency, yieldetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yProShares UltraShort Nasdaq Biotechnology is an exchange-traded fund (ETF) designed to provide leveraged inverse exposure to the Nasdaq Biotechnology Index. Its primary function is to deliver twice the inverse (or opposite) of the daily performance of the index. This allows investors to profit from declines in the biotechnology sector. The fund is particularly geared towards sophisticated investors who have a bearish outlook on the biotechnology industry or those seeking to hedge their long positions within this sector. The Nasdaq Biotechnology Index it tracks includes a wide range of companies involved in medical research, pharmaceutical development, and biotechnological innovations. ProShares UltraShort Nasdaq Biotechnology plays a significant role in the financial market by offering unique benefits such as liquidity, transparency, and the potential for short-term gains in volatile markets. It allows investors to gain easy access to leveraged market strategies without the need to directly engage in short selling individual biotech stocks. However, due to its leveraged nature, it is more suited for short-term investment horizons and requires careful management of trading risk.
30-day change
-$171.7K
90-day change
—
Current AUM: $2,249,782. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for BIS are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.